Transcriptomic profiling of cells treated with a novel CDK12/13 inhibitor, CTX-439

ABSTRACT: We developed a novel clinical-grade CDK12/13 inhibitor, CTX-439, and analyzed transcriptomic changes upon CTX-439 treatment. CTX-439 downregulated a large number of genes including DDR genes. By analyzing rRNA-depleted nuclear RNA, CTX-439 caused a defect in 3' end processing, showing an increased readthrough transcription. This caused rapid MCL1 downregulation, which can be combined with BCL-xL inhibition to induce apoptosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE291144 | GEO | 2026/09/14

REPOSITORIES: GEO